Figure 1. In contrast to their gene effects, muscarinic agonists (muscarine, oxotremorine, and acetylcholine) did not alter the proliferation of SH-SY5Y cells. Cells were plated at 50,000/well and were exposed to muscarinic agonists, vehicle or insulin for 24 hours. Increase in cell number was measured by Alamar blue assay.

Figure 1, Supplement 1

3000

0

500

1000

1500

2000

2500

Inte

nsi

ty U

nit

s x

10-3

DMSO Oxotremorine (mol/L)

Insulin Muscarine(mol/L)

Acetylcholine(mol/L)

0.4 2 10 50 200 nM0.4 2 10 50 0.4 2 10 50

INACTIVE COMPOUND NAME Pharmacological Class INACTIVE COMPOUND NAME Pharmacological Class

R-(+)-8-Hydroxy-DPAT 5HT1A agonist Risperidone D2/5HT2A antagonist(+)-7-Hydroxy-2-(DI-n-Propyl-Amino)Tetralin

5HT1A agonist S-(+)-PD 128,907 D2/D3 agonist

Trazodone5HT1A agonist + 5HT2A antagonist

PD 168,077 Maleate D4 Agnoist

NAN-190 5HT1A antagonist Bupropion DA uptake site antagonist

S-(-)-UH-301 5-HT1A antagonist Nomifensine DA uptake site antagonist

(+)-DOI 5HT2A agonist 5,5-Diphenlyhydantoin Dilantin; antiepileptic

Quipazine 5HT2A agonist3-Methyl-GABA (2:1 salt with naphthalene-1,5-disulfonic acid)

GABA agonist

Ketanserin 5HT2A antagonist Gabapentin GABA agonist

5-Hydroxytryptamine (serotonin)Agonist at 14 serotonin receptors

Muscimol GABA agonist

Clonidine alpha 2 agonist Corticosterone Glucocorticoid agonist

Ethosuximide Antiepileptic Dexamethasone-Water Soluble Glucocorticoid agonist

Felbamate Antiepileptic 1-(m-Chlorophenly)-Piperazine Glutamate antagonist

Vigabatrin Antiepileptic L-Glutamine Glutamate precursor

Phenelzine Antihistamine Riluzole Hydrochloride Glutamate uptake blocker

Imidazole Antiinflammatory GlycineGlycine transporter substrate; glycine receptor agonist

L-Ascorbic Acid Antioxidant Histamine H1/H2/H3 agonist

Pindolol Beta antagonist Cimetidine H2 antagonist

Forskolin cAMP stimulator Iproniazid MAO inhibitor

(+)-SKF-38393 D1 agonist Carbamazepine Mood stabilizer

Apomorphine HCl hemihydrate, R(-)D1/D2 agonist Lamotrigine Mood stabilizer

(+)-Butaclamol Hydrochloride D2 antag Lithium Chloride Mood stabilizer

Chlorpromazine D2 antag and H1 antag Desipramine NE reuptake antagonist

Fluphenazine D2 antag and H1 antag (-)-Nicotine Nicotinic agonist

Thioridazine D2 antag and H1 antag NMDA NMDA agonist

(-)-Sulpiride D2 antagonist Kynurenic Acid NMDA antagonist

Haloperidol D2 antagonist Clozapine Non-specific antipsychotic sites

Pimozide D2 antagonist (-)-Butaclamol Hydrochloride Non-specific, non-D2

S(-) Raclorpride (+)-tartrate salt D2 antagonist Buspirone partial 5HT1A agonist

Spiperone D2 antagonist Imipramine SNRI

Thiothixene D2 antagonist Clomipramine SSRI

Pimozide D2 antagonist Fluoxetine Hydrochloride SSRI

Sulpiride D2 antagonist Progesterone Steroid

Table 1, Supplement 1

Table 1. Pharmacological profiles of 63 inactive compounds. None of these altered MPHTSSM gene expression in the SH-SY5Y cells, and are representative of the mostly inactive, 1,940 unique compounds tested. Abbreviations: 5-HT, serotonin; cAMP, cyclic adenosine monophosphate; D, dopamine; GABA, gamma-aminobutyric acid; H, histamine; MAO, monoamine oxidase; NE, norepinephrine; NMDA, N-methyl-D-aspartate; SSNI, selective serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.